Actively Recruiting
Study of Switching from Mavacamten to Aficamten for Treatment of Obstructive Hypertrophic Cardiomyopathy
Led by Oregon Health and Science University · Updated on 2026-05-20
40
Participants Needed
2
Research Sites
10 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the safety, feasibility, and effectiveness of switching from mavacamten to aficamten in patients with obstructive hypertrophic cardiomyopathy oHCM. This study focuses on patients who have documented oHCM with significant left ventricular outflow tract LVOT obstruction and are already receiving mavacamten. The study is investigator-initiated and conducted at two centers. Participants will stop taking mavacamten on day 1 of the study and then start aficamten two weeks later. This seamless transition aims to assess how well patients tolerate the change and the impact on their heart condition. The study is designed as an interventional trial without masking, and the treatment phase lasts up to 16 weeks. During the study, participants will be closely monitored for safety outcomes and changes in heart function. Assessments include measurements of LVOT gradients at rest and during Valsalva maneuver, blood tests for heart stress markers like NT-proBNP and troponin I, and evaluation of symptoms using the New York Heart Association functional classification. The total participation time covers up to 16 weeks with regular evaluations to track the transition effects.
CONDITIONS
Brief Title
Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy
Research Team
A
Ahmad Masri
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
